Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis buys exclusive rights to a promising dermatologic drug

Novartis announced that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106.

French CDMO will manufacture innovative cancer treatments for Novartis

Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).

Regenxbio receives $100 million license payment from Novartis

REGENXBIO announced that it has received an accelerated license payment of $100 million under its license agreement with AveXis, due to the acquisition of AveXis by Novartis.

Top pharma players place their stakes on Chinese market

china street
Pharmaceutical giant Bayer reported a robust growth in its pharmaceutical business in China, as its total sales stood at 17 billion yuan ($2.67 billion) in 2017, a year-on-year growth of 18.3 percent.

Novartis launched its novel FocalView clinical trials application

Novartis announced the launch of FocalView, an ophthalmic digital research platform. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients.

Novartis will invest $100 million in development of antimalarials

Novartis announced a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting.

Novartis buys gene therapy company AveXis

Novartis announced that it has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based clinical stage gene therapy company for $8.7 billion.

Bayer, Novartis and Teva topped February sales rankings in Russia

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%.

Novartis sells its stake in consumer healthcare joint venture to GSK

Novartis announced that it has entered into an agreement with GlaxoSmithKline (GSK) to divest its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion.

Tilray set up a strategic alliance with a leading Canadian pharma company

medicinal cannabis
Tilray, a licensed producer of medical cannabis, signed a binding letter of intent to be the collaborator of a major pharma company to accelerate innovation and increase availability of high quality medical cannabis products.

Novartis advances its clinical trials program with Science 37

Novartis announced an additional strategic alliance with Science 37, a leader in decentralized clinical trial technology and design, to initiate up to 10 new clinical trials over the next three years.

Novartis is involved in Greek bribe scandal

Greece's parliament has linked ten prominent politicians to a bribery scandal involving Swiss healthcare company Novartis. The Greek parliament announced on Tuesday the results of a judicial investiga...

Novartis exclusively licensed gene therapy drug

Novartis announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US

AIPM elects Vadim Vlasov as Chairman of its Board of Directors

The Association of International Pharmaceutical Manufacturers announced that Vadim Vlasov, the President of Novartis Group Russia, was elected the Chairman of AIPM Board of Directors

Novartis plans to buy French radiopharmaceutical company

Global healthcare company Novartis has announced plans to acquire Advanced Accelerator Applications, a radiopharmaceutical firm established by physicist Stefano Buono in 2002

FAS of Russia identified unjustified 35% overpricing of Tyverb

FAS Russia
In April 2017, the FAS Russia initiated a case on the grounds that Novartis Pharma had violated Clause 1 of Part 1 of Article 10 of the Law on Protection of Competition